| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 36,321,704 | 40,211,097 | 14,364,248 | 18,880,345 |
| Cost of manufacturing | 22,248,671 | 12,985,127 | 8,244,907 | 10,682,917 |
| Gross profit | 14,073,033 | 27,225,970 | 6,119,341 | 8,197,428 |
| Research and development | 1,385,306 | 1,674,964 | 1,793,803 | 1,966,094 |
| General and administrative | 4,029,199 | 3,404,084 | 2,724,616 | 2,273,744 |
| Non-cash compensation through issuance of stock options | 49,918 | 52,329 | 70,578 | 52,329 |
| Depreciation and amortization | 394,864 | 394,886 | 432,534 | 420,318 |
| Total operating expenses | 5,859,287 | 5,526,263 | 5,021,531 | 4,712,485 |
| Interest expense and amortization of debt issuance costs | - | 158,926 | 77,607 | 255,136 |
| Income from operations | 8,213,746 | 21,699,707 | 1,097,810 | 3,484,943 |
| Change in fair value of derivative financial instruments - warrants | 7,519,649 | -22,109,537 | -11,729,368 | -12,754,735 |
| Interest expense and amortization of debt issuance costs | 82,470 | - | - | - |
| Interest income | 4,922 | 4,542 | 5,092 | 5,902 |
| Other income | 34,500 | 0 | 51,308 | - |
| Other income (expense), net | 7,476,601 | -22,263,921 | -11,750,575 | -13,003,969 |
| Income (loss) before income taxes | 15,690,347 | -564,214 | -10,652,765 | -9,519,026 |
| Income tax expense | 1,987,940 | 5,320,501 | 239,175 | 1,517,203 |
| Net income (loss) attributable to common shareholders | 13,702,407 | -5,884,715 | -10,891,940 | -11,036,229 |
| Basic net income (loss) per share attributable to common shareholders | 0.01 | -0.01 | -0.01 | -0.01 |
| Basic weighted average common stock outstanding | 1,071,897,174 | 1,068,363,108 | 1,068,273,108 | 1,068,273,108 |
| Diluted net income (loss) per share attributable to common shareholders | 0.01 | -0.01 | -0.01 | -0.01 |
| Diluted weighted average common stock outstanding | 1,141,536,381 | 1,068,363,108 | 1,068,273,108 | 1,068,273,108 |
ELITE PHARMACEUTICALS INC NV (ELTP)
ELITE PHARMACEUTICALS INC NV (ELTP)